Theravance Biopharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in two upcoming investor conferences: the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 11:10 am ET and the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 1:30 pm ET. Both events will be webcast, accessible via Theravance.com. The company focuses on delivering innovative medicines, including the FDA-approved YUPELRI® for COPD. Event replays will be available for 30 days.

DUBLIN, Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be webcast:

• Morgan Stanley 20^th Annual Global Healthcare Conference on Tuesday, September 13 at 11:10 am ET (8:10 am PT/4:10 pm IST)
• H.C. Wainwright 24^th Annual Global Investment Conference on Wednesday, September 14 at 1:30 pm ET (10:30 am PT/6:30 pm IST)

Webcasts of the events may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant unmet patient needs. 

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact: Gail B. Cohen
Corporate Communications / 917-214-6603

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-upcoming-investor-conferences-301618019.html

SOURCE Theravance Biopharma, Inc.

FAQ

What investor conferences will Theravance Biopharma participate in September 2022?

Theravance Biopharma will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 and the H.C. Wainwright 24th Annual Global Investment Conference on September 14.

What is the date and time of the Morgan Stanley conference for Theravance Biopharma?

The Morgan Stanley conference will take place on September 13, 2022, at 11:10 am ET.

When is the H.C. Wainwright conference for Theravance Biopharma scheduled?

The H.C. Wainwright conference is scheduled for September 14, 2022, at 1:30 pm ET.

How can I access the webcasts of Theravance Biopharma's investor conferences?

The webcasts can be accessed on Theravance.com under the Investors section, Presentations and Events.

How long will the webcasts of the conferences be available for replay?

The replay of the webcasts will be archived on Theravance's website for 30 days.

What is the focus of Theravance Biopharma as a company?

Theravance Biopharma focuses on delivering innovative medicines, including the FDA-approved YUPELRI® for chronic obstructive pulmonary disease (COPD).